Biomarker may help identify men with prostate cancer at greater risk of tumor metastasis

Ten percent of patients with prostate cancer develop locally invasive and metastatic disease, which increases the severity of the disease and likelihood of death and limits treatment options. A report in The American Journal of Pathology indicates that a significantly lower presence of syntaphilin (SNPH) — a mitochondrial protein — within the tumor’s central core versus at the tumor’s invasive outer edge, may identify patients at increased risk of metastasis. These patients may require more rigorous testing, surveillance, and treatment.
Source: EurekaAlert,